Ovid Therapeutics Reports Second Quarter 2023 Financial Results and Corporate UpdatesGlobeNewsWire • 08/04/23
Ovid Therapeutics to Present at the BTIG Virtual Biotechnology Conference 2023GlobeNewsWire • 08/01/23
Ovid Therapeutics Expands Its Scientific Leadership Team & Appoints Chief Strategy OfficerGlobeNewsWire • 06/28/23
Ovid Therapeutics: Bullish Outlook Strengthened By Positive 2-Year Open-Label Trial ResultsSeeking Alpha • 06/13/23
Ovid Therapeutics Reports First Quarter 2023 Financial Results and Corporate UpdatesGlobeNewsWire • 05/05/23
Ovid Therapeutics Announces Collaboration with Graviton Bioscience, Proven Developers of Selective ROCK2 InhibitorsGlobeNewsWire • 05/01/23
Long-term Safety & Efficacy Findings from Soticlestat Open Label Extension Study Presented by Takeda at American Academy of Neurology Annual MeetingGlobeNewsWire • 04/27/23
Ovid Therapeutics (OVID) Upgraded to Buy: Here's What You Should KnowZacks Investment Research • 04/12/23
Ovid Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare ConferenceGlobeNewsWire • 04/10/23
Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2022 Financial ResultsGlobeNewsWire • 03/13/23
Ovid Therapeutics to Present at the 2nd Annual Needham Virtual Neuroscience ForumGlobeNewsWire • 03/09/23
Studies Published in Cell Reports Medicine Validate the Potential of Direct KCC2 Activation in Resistant SeizuresGlobeNewsWire • 03/08/23
Ovid Therapeutics Expands Epilepsy Development Expertise with New AppointmentsGlobeNewsWire • 02/08/23
Ovid Therapeutics to Present Data on Its Epilepsy Programs at American Epilepsy Society Annual Meeting (2022)GlobeNewsWire • 12/02/22
Ovid Therapeutics Reports Third Quarter 2022 Financial Results and Corporate HighlightsGlobeNewsWire • 11/08/22
Ovid Therapeutics to Present at the Ladenburg Thalmann 2022 Healthcare ConferenceGlobeNewsWire • 09/27/22
Ovid Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment ConferenceGlobeNewsWire • 09/07/22
Ovid Therapeutics Reports Second Quarter 2022 Financial Results and Corporate HighlightsGlobeNewsWire • 08/09/22
Ovid Therapeutics Presents Preclinical Data on OV329 at the Epilepsy Foundation Pipeline ConferenceGlobeNewsWire • 06/06/22
Ovid Therapeutics Reports First Quarter 2022 Financial Results and Corporate HighlightsGlobeNewsWire • 05/10/22
Ovid Therapeutics to Present at the 21st Annual Needham Virtual Healthcare ConferenceGlobeNewsWire • 04/08/22